- Home
- FINV vs LTGO Comparison
FINV vs LTGO Comparison
Compare FINV & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FINV | LTGO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | FINV | LTGO |
|---|---|---|
| Price | $3.37 | $24.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.10 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 206.3K |
| Earning Date | 05-19-2026 | N/A |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.58 | N/A |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.22 | $17.22 |
| 52 Week High | $8.05 | $25.93 |
Technical Indicators
Market Signals| Indicator | FINV | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 29.94 | 69.10 |
| Support Level | N/A | $21.26 |
| Resistance Level | $5.17 | $25.47 |
| Average True Range (ATR) | 0.22 | 2.02 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 12.72 | 69.14 |
Price Performance
Historical ComparisonAbout FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.